Oxford BioDynamics (LON:OBD) Stock Falls 10.6% – Time to Sell?
by Michael Walen · The Markets DailyShares of Oxford BioDynamics Plc (LON:OBD – Get Free Report) were down 10.6% on Monday. The stock traded as low as GBX 0.10 and last traded at GBX 0.10. Approximately 86,794,008 shares traded hands during mid-day trading, an increase of 278% from the average session volume of 22,947,174 shares. The stock had previously closed at GBX 0.11.
Oxford BioDynamics Trading Down 10.6%
The company has a current ratio of 2.01, a quick ratio of 2.80 and a debt-to-equity ratio of 131.61. The firm has a market cap of £4.33 million, a P/E ratio of -0.51 and a beta of 0.42. The stock has a 50 day simple moving average of GBX 0.12 and a 200-day simple moving average of GBX 0.16.
Oxford BioDynamics Company Profile
Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.